|Videos|September 12, 2016

Why Should We Start Using Narrow Spectrum Antibiotics?

Kirk Hevener, PharmD, PhD, assistant professor of Biomedical and Pharmaceutical Sciences at Idaho State University, College of Pharmacy, discusses the advantages of narrow spectrum antibiotics.

Kirk Hevener, PharmD, PhD, assistant professor of Biomedical and Pharmaceutical Sciences at Idaho State University, College of Pharmacy, discusses the advantages of narrow spectrum antibiotics.

Interview Transcript (slightly modified for readability)

“By narrowing in on specific organisms and specifically targeting and going after, say, [Streptococcus] mutans in my case, or [Clostridium] difficile, which there [are] a lot of people that are looking at very narrow spectrum C. diff targets, you’re sparing other bacteria in the microbiome, the bulk of all the bacteria you have in your body.

By sparing those other bacteria, you’re not putting selective pressure on those other bacteria to evolve to be resistant to the antibacterials that you are using. So yes, absolutely: narrow spectrum antibacterial use will limit the development of bacterial resistance.”


Related to this article

How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.